A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
← catalyst calendarNCT07206225 · readout in 1,259 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
294estimated
Sites
68
Countries
France, Israel, South Korea +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-06 | actual | When the study began enrolling |
| Primary completion | 2030-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-01-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-muscle Invasive Bladder Cancer
Interventions
- Drug: PF-08052667 — also filed as SGN-B6N
- Drug: Sasanlimab — also filed as PF-06801591
- Drug: BCG
- Drug: PF-02921367 — also filed as DDM
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants only
measured Day of first dose (Day 1) Up to 21 days
Number of participants with adverse events (AEs) in Part 1 and Part 2 participants only
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Number of participants with laboratory abnormalities in Part 1 and Part 2 participants only
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Recurrence-free survival (RFS) in Part 3 participants only
measured Through end of study and up to approximately 2 years
Event-free survival (EFS) in Part 3 participants only
measured Through end of study and up to approximately 2 years
Publications
- PMID 42008114 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed